Skip to content
10-K

Annual Report

Statera Biopharma, Inc.

0001437749-22-023703

← back to feed
Filed
Oct 6, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Aug 31, 2022 51.14M sh
Capex FY 2021 · Dec 31, 2021 $182.97K
Capex FY 2021 · Dec 31, 2020 $9.64K
Operating Cash Flow FY 2021 · Dec 31, 2021 −$28.19M
Operating Cash Flow restated FY 2021 · Dec 31, 2020 −$5.08M
Long Term Debt FY 2021 · Dec 31, 2021 $10.63M
Long Term Debt FY 2021 · Dec 31, 2020 $0
Short Term Investments FY 2021 · Dec 31, 2021 $134.6K
Short Term Investments restated FY 2021 · Dec 31, 2020 $0
Cash And Equivalents FY 2021 · Dec 31, 2021 $1.84M
Cash And Equivalents restated FY 2021 · Dec 31, 2020 $593.87K
Stockholders Equity FY 2021 · Dec 31, 2021 −$1.57M
Current Liabilities FY 2021 · Dec 31, 2021 $11.25M
Current Liabilities restated FY 2021 · Dec 31, 2020 $4.62M
Total Liabilities FY 2021 · Dec 31, 2021 $22.68M
Total Liabilities restated FY 2021 · Dec 31, 2020 $4.69M
Current Assets FY 2021 · Dec 31, 2021 $4.15M
Current Assets restated FY 2021 · Dec 31, 2020 $925.75K
Total Assets FY 2021 · Dec 31, 2021 $21.17M
Total Assets restated FY 2021 · Dec 31, 2020 $1.04M
Eps Basic FY 2021 · Dec 31, 2021 −$2.90
Eps Basic FY 2021 · Dec 31, 2020 −$1.66
Rd Expense FY 2021 · Dec 31, 2021 $11.83M
Rd Expense restated FY 2021 · Dec 31, 2020 $5.26M
Net Income FY 2021 · Dec 31, 2021 −$101.85M
Net Income restated FY 2021 · Dec 31, 2020 −$12.09M
Operating Income FY 2021 · Dec 31, 2021 −$98.34M
Operating Income restated FY 2021 · Dec 31, 2020 −$10.5M
Gross Profit FY 2021 · Dec 31, 2021 $998.72K
Gross Profit FY 2021 · Dec 31, 2020 $0
Cost Of Revenue FY 2021 · Dec 31, 2021 $488.31K
Cost Of Revenue FY 2021 · Dec 31, 2020 $0
Revenue FY 2021 · Dec 31, 2021 $1.49M
Revenue restated FY 2021 · Dec 31, 2020 $0